Literature DB >> 7522959

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Z Culig1, A Hobisch, M V Cronauer, C Radmayr, J Trapman, A Hittmair, G Bartsch, H Klocker.   

Abstract

Aberrant activation of the androgen receptor (AR) may be one of the mechanisms which contribute to progression of prostatic carcinoma to an androgen-independent stage. We investigated effects of growth factors on stimulation of the AR-mediated gene transcription in human prostatic tumor cell lines. DU-145 cells, which do not contain endogenous AR, were cotransfected with an androgen-inducible chloramphenicol acetyltransferase (CAT) reporter gene and an AR expression vector. The reporter gene (CAT) was driven either by artificial promoters consisting of one or two androgen-responsive elements in front of a TATA box or by the promoter of the prostate-specific antigen (PSA) gene, a naturally occurring androgen-inducible promoter. Insulin-like growth factor-I (IGF-I), at a concentration of 50 ng/ml, stimulated AR-mediated reporter gene transcription to the same extent as the synthetic androgen methyltrienolone. This growth factor was effective irrespective of the nature of the androgen-inducible promoter. Keratinocyte growth factor (KGF) and epidermal growth factor (EGF), at concentrations of 50 ng/ml, activated CAT reporter gene transcription only in experiments in which the artificial promoter with two androgen-responsive elements was used. Insulin-like growth factor-II and basic fibroblast growth factor displayed no effect on AR-mediated gene transcription. None of the growth factors stimulated reporter gene activity in control experiments when added to cells cotransfected with the CAT gene and an empty expression vector. AR activation by IGF-I, KGF, and EGF was completely inhibited by the pure AR antagonist casodex, showing that these effects are AR mediated. Activation of endogenous AR by growth factors was studied in the LNCaP cell line by determination of PSA secretion. IGF-I, at a concentration of 50 ng/ml, increased the PSA level in the supernatant of this cell line 5-fold. Again, the IGF-I effect on PSA secretion was blocked by casodex. Our results provide evidence that IGF-I, KGF, and EGF directly activate the AR in the absence of androgens, which means that the androgen-signaling chain may be activated by growth factors in an androgen-depleted environment. These findings may have implications for endocrine therapy for metastatic prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522959

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  222 in total

1.  Serum prosaposin levels are increased in patients with advanced prostate cancer.

Authors:  Shahriar Koochekpour; Siyi Hu; Cruz Vellasco-Gonzalez; Ruiz Bernardo; Gissu Azabdaftari; Guodong Zhu; Haiyen E Zhau; Leland W K Chung; Robert L Vessella
Journal:  Prostate       Date:  2011-05-31       Impact factor: 4.104

Review 2.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 3.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

4.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

5.  Androgen receptor overexpression is neuroprotective in experimental stroke.

Authors:  Patricia Ayala; Masayoshi Uchida; Kozaburo Akiyoshi; Jian Cheng; Joel Hashimoto; Taiping Jia; Oline K Ronnekleiv; Stephanie J Murphy; Kristine M Wiren; Patricia D Hurn
Journal:  Transl Stroke Res       Date:  2011-04-15       Impact factor: 6.829

Review 6.  Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment.

Authors:  Melanie J Grubisha; Donald B DeFranco
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

7.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

8.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

Review 9.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

10.  Activation of androgen receptor function by a novel nuclear protein kinase.

Authors:  A M Moilanen; U Karvonen; H Poukka; O A Jänne; J J Palvimo
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.